China Healthcare Reform and Its Impact on IVD, Medical Device and Pharmaceutical Markets (Market Size Estimates, Regional Healthcare Market Breakouts, Demographics and Regulation)
Kalorama Information
October 15, 2011 167 Pages - SKU: KLI6609070
|
|
Countries covered: China
China's rapid economic development and the numerous steps of reform undertaken by the Chinese central government since 1997 have had clear and observable effects upon China's total healthcare services market and its product markets for pharmaceuticals, medical devices, and in vitro diagnostics (IVD). This progress has been augmented by a Reform program in 2009, which includes increased funding to improve services.
What are the workings of China's healthcare system? How much progress has been made towards the promised vision of the CPCC in 2008 to provide "convenient and affordable access" to its people? What are the effects on foreign companies seeking to benefit from an increase in healthcare-related funding? Where are the best opportunities in China for marketers? Kalorama analyst Emil Salazar focuses on these questions and more.
The report contains a comprehensive overview of the Chinese healthcare system with important data for marketers to China. It discusses healthcare reform plans and where funds were spent. It also describes the role foreign companies play. As part of its analysis, the report includes the following information:
- Statistics on Chinese Hospitals, Community Health Centers and Clinics
- Top and Bottom City Markets for Urban Healthcare
- Top and Bottom Rural Regions
- Challenges for Foreign-Owned MNCs in China
- Government Healthcare Spending
- Foreign-Invested Manufacturing Enterprises in China
- Share of Government Funded Healthcare vs. Out of Pocket
- Domestic Healthcare Industries
- Population and Age Statistics
- Incidence Rates for Infectious Diseases
- Cancer Rates in China
- Regulation of Drugs and Devices in China
- U.S. Product Exports to China
- Key Analyst Conclusions
In addition to providing useful background information and a thorough analysis of China's healthcare changes, the report provides data for business planning. It also takes a look at the status and forecast of the three key healthcare markets in China:
- The Chinese Market for IVD products
- Regional Breakout of the Chinese IVD Market
(Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
- The Chinese Market for Medical Device Products
- Regional Breakout of the Chinese Medical Device Market
(Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
- Segment Breakout of the Chinese Medical Device Market(Surgical Instrument, Disposable, Patient Monitoring, IVD, Imaging, Orthopedic, Other)
- The Chinese Market for Pharmaceutical Products
- Regional Breakout of the Pharmaceutical Market
(Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
- Segment Breakout of the Pharmaceutical Market
(Cardiovascular, Gastrointestinal, Anti-Infectives, Neurotherapeutics, Oncology, Respiratory, Other)
This essential resource for anyone marketing a healthcare product to China was constructed using a combination of primary and secondary sources. Corporate reports, trade publications government information and medical journals, previous market research studies conducted by Kalorama and other sources were used. In some cases, interviews were used to determine forecasts and key trends.
All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
For Kalorama's take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information's Key Point Blog at http://kaloramakeypoint.blogspot.com/
|
Additional InformationChina's Second Tier Cities May Provide Medical Market Opportunities, Kalorama Reports
Companies marketing pharmaceutical, medical device and diagnostic products may find the best growth opportunities in China's second tier cities, according to a recently released Kalorama Information report: China Healthcare Reform and Its Impact on IVD, Medical Device and Pharmaceutical Markets.
Kalorama notes that the percentage of Chinese residing in urban healthcare markets rose from 36% to 50% between 2000 and 2010. While major urban healthcare markets - concentrated around metropolises like Shanghai, Hong Kong, Beijing and Guangzhou - have long featured high demand for a range of pharmaceutical and medical devices, pronounced urbanization throughout China has nurtured demand in second-tier cities along China’s coastal provinces, and also in the middle and western half of the country. Economic development in Chinese cities and urban migration continue to bolster the urban healthcare market. Rural residents are also apt to pursue specialty outpatient and inpatient care at city hospitals.
According to Kalorama Information, the 2010 urban healthcare market in China (including Hong Kong) was over three times the size of the rural healthcare market with a volume of approximately 1.24 trillion yuan (~$183.2 billion). Even with its apparent priorities in improving rural healthcare, the Chinese government must manage and fund more diversified and expensive urban healthcare systems that are equally beset by challenges in coverage. Recently expanded national health plans provided over five times more total reimbursements to urban enrollees than to rural enrollees, according to Kalorama.
In its market research report, Kalorama also identifies key urban healthcare markets by region.
"Cities like Chengdu, Chongqing in West China; and Zhengzhou and Wuhan in Central China are already the beneficiaries of MNC R&D investment," said analyst Emil Salazar, "but are also targets for medical product sales and ideal hubs for provincial and regional distribution networks for pharmaceuticals, IVD reagents and other medical supplies." Among other findings from Kalorama's report, the provinces of Southwestern and Central China are projected to see the greatest market growth for pharmaceuticals and medical devices over the next four years with strong demand out of their emerging regional metropolises.
The full report from Kalorama Information, China Healthcare Reform and Its Impact on IVD, Medical Device and Pharmaceutical Markets, includes breakdowns of the IVD, pharmaceutical and medical device markets by region with figures from 2004 to 2015.
CHAPTER ONE: EXECUTIVE SUMMARY
- Healthcare in China
- Healthcare Reform and Market Impact
- Rural Healthcare Market in Era of Reform
- Urban Healthcare Market in Era of Reform
- China’s IVD Market in an Era of Reform
- China’s Medical Devices Market in an Era of Reform
- China’s Pharmaceuticals Market in an Era of Reform
- Major Findings
CHAPTER TWO: HEALTHCARE IN CHINA - PRIMARY INDICATORS AND A NEED FOR REFORM
- Introduction
- Barefoot Doctors and the Rural Cooperative Medical Scheme (RCMS)
- China’s Economic Reform Impacts Healthcare
- New Rural Cooperative Medical Scheme (NRCMS) and Government Recommitment to Reform
- China on the Eve of Contemporary Healthcare Reform
CHAPTER THREE: CHINA’S “REFORM” HEALTHCARE MARKET AND ITS SHAPING OF RURAL, URBAN, REGIONAL AND PROVINCIAL MARKETS
- Introduction
- China’s 2009-2011 Healthcare Reform in Its Main Features and Provisions
- Healthcare Reform on the “Grassroots” Level - The Many Chinas in Focus
- The Contemporary Rural Healthcare Market in China - Major Regions, Institutions and Landscape
- Rural China Healthcare Market from the NRCMS to the End of Healthcare Reform under the 12th Five-Year Plan (2004-2015) - Historical and Projected Market Sizes and Segmentation
- Urban Healthcare Markets in China and their Trajectory through Reform (2004-2015)
- Foreign Medical Product Suppliers Penetrate the Chinese Market
CHAPTER FOUR: DIAGNOSTICS IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015
- Introduction
- Demand-Side Drivers in the Chinese IVD Market
- Diabetes
- Cancer
- Allergy
- Infectious Disease
- Healthcare System/ Reform Supply-Side Drivers
- Physician Office Laboratories (POL
- Self-Testing
- Hospital and Private Laboratories
- Research and Technology Sector
- Market Size and Projections
- Market Distribution and The State of The Industry
- Domestic Chinese IVD Industry
- Regulation
CHAPTER FIVE: MEDICAL DEVICES IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015
- Introduction
- Demand-Side Drivers in the Chinese Medical Device Market
- Cancer
- Cardiovascular Diseases
- Aging
- Healthcare System/Reform - Supply-Side Drivers
- Hospitals
- Specialty Treatment Clinics
- Public Clinics, Health Centers and “Grass Roots” Medical Institutions
- Market Size and Projections
- Market Distribution and the State of the Industry
- Foreign Manufacturers
- Domestic Chinese IVD Industry
- Regulation
- Manufacturing Enterprise Approvals
- Cost Controls for Medical Procedures and Reimbursements
- Device Approval
CHAPTER SIX: PHARMACEUTICALS IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015
- Introduction
- Demand-Side Drivers in the Chinese Pharmaceuticals Market
- Diabetes
- Hypertension and Heart Disease
- Cancer
- Infectious Diseases
- Self-Medication
- Supply-Side Drivers (Healthcare Reform) and Market Channels
- Hospital Pharmacies
- Retail Pharmacies
- Other Commercial Channels - Mass Merchants, Mail Order and Online
- Market Size and Projections
MARKET DISTRIBUTION AND THE STATE OF THE INDUSTRY
- “Big Pharma” - western MNCs in China
- Domestic Chinese Pharma Industry
REGULATION
- Manufacturing Enterprise Approvals
- Pricing Controls at Manfacturer-Level
- Pricing Controls at Pharmacy-Level
- Drug Approval
- Intellectual Property Protection (IPP)
CHAPTER SEVEN: CONCLUSIONS
- Conclusion One
- Conclusion Two
- Conclusion Three
- Conclusion Four
- Conclusion Five
- Conclusion Six
- Conclusion Seven
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: Government-Run Urban Health Insurance Programs in China
- Figure 1-1: Chinese Healthcare Reform Government Funding
Breakdown (2009-2011)
- Figure 1-2: Rural and Urban China Healthcare Market (Insurance and
Out-of-Pocket Payments) (2004-2015) (billion yuan)
- Figure 1-3: IVD, Pharmaceuticals and Medical Devices Markets
in China (2004-2015) (billions $)
CHAPTER TWO: HEALTHCARE IN CHINA - PRIMARY INDICATORS
AND A NEED FOR REFORM
- Figure 2-1: Chinese National Population (% Urban/Rural)
- Figure 2-2: Chinese Government Health Expenditures (in billion yuan and
% of total health expenditures) (1980-2009)
- Figure 2-3: Average Inpatient Visit Costs and Bed Utilization at Chinese
Public Hospitals (1985-2010)
- Figure 2-4: Gross National Income (GNI) Per Capita - China and OECD Member Country Average (1980-2009)
- Figure 2-5: Chinese Bureaucratic and Market Divisions (East, Middle, West China)
- Figure 2-6: Private Hospitals in China by Region (East / Middle / West) (2010)
- Figure 2-7: Number of Private and Public Hospitals in China (1980-2010)
- Figure 2-8: Income Sources for Government-Run Hospitals (%)
- Figure 2-9: New Rural Cooperative Medical Scheme Enrollment (2004-2010)
- Table 2-1: Government-Run Urban Health Insurance Programs in China
- Figure 2-10: Government Health Insurance Coverage (2003 and 2008)
- Figure 2-11: Hospital Visits in China (millions) (1995-2010)
- Table 2-2: Government Healthcare Expenditure and GDP Growth Rates (China and Selected Comparison Countries; 2000-2008
- Figure 2-12: Chinese Population by Age (Total; 1990/2000/2009) (%)
CHAPTER THREE: CHINA’S “REFORM” HEALTHCARE MARKET AND ITS SHAPING OF RURAL, URBAN, REGIONAL AND PROVINCIAL MARKETS
- Figure 3-1: Chinese Healthcare Reform Government Funding Breakdown (2009-2011)
- Figure 3-2: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality (2010)
- Rural China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance
Expenditures) (2004-2010) (billion yuan)
- Table 3-1: Rural China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2004-2010) (billion yuan)
- Figure 3-4: Regional Shares of Reimbursement Funds under NRCMS (2010) (East/Middle/West China) (%)
- Figure 3-5: Rural China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2010-2015 Projection) (billion yuan)
- Table 3-2: Rural China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2010-2015 Projection) (billion yuan)
- Table 3-3: Top and Bottom Five Provincial Markets for Rural Healthcare by Gain and Loss in National Market Share (2010-2015)
- Figure 3-6: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality (2010)
- Figure 3-7: Outpatient Visits in the Urban Healthcare Market, 2010 (Hospitals, Community Health Centers, Community Health Stations, Clinics, Other) (millions of visits)
- Figure 3-8: Composition of Chinese Hospital Sector by
Number of Beds, 2000-2010 (percent)
- Figure 3-9: Urban China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2004-2010) (billion yuan)
- Table 3-4: Urban China Healthcare Market (Total Consumer/Out-of-Pocket/Insurance Expenditures) (2004-2010) (billion yuan)
- Figure 3-10: Top and Bottom Five Provincial Markets for Urban Healthcare by Gain and Loss in National Market Share (2010-2015)
- Figure 3-11: U.S. Medical Product Export Growth to China (1990-2010)
- Figure 3-12: Total U.S.-EU Exports to China - Pharmaceutical Products and Medical Devices (2002-2010) (millions of U.S. dollars)
- Figure 3-13: Inbound Foreign Direct Investment in Medical Product Manufacturing in China (2002-2010)
- Figure 3-14: Foreign-Invested Manufacturing Enterprises in China (1980-2010)
- Figure 3-15: Foreign-Invested Manufacturing Enterprises in China by Province/Municipality (1995-2010)
CHAPTER FOUR: DIAGNOSTICS IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015
- Figure 4-1: Chronic Disease Morbidity Rates in Urban China - Hypertension, Diabetes, Cerebrovascular Disease (Stroke), Chronic Obstructive Pulmonary Disease, Heart Disease (per thousand [0/00]) (2003/2008)
- Figure 4-2: Chronic Disease Morbidity Rates in Rural China - Hypertension,
Diabetes, Stroke, Chronic Obstructive Pulmonary Disease, Heart Disease (2003/2008)
- Figure 4-3: Cancer Mortality Rates in China - Lung, Liver, Stomach, Esophageal,
Colon, Leukemia, Brain, Breast, Pancreatic (Per 100,000) (2005)
- Table 4-1 Incidence Rates for Top Ten Notifiable Infectious Diseases (2010)
- Table 4-2 Selected Preventative Medicine Opportunities
- Table 4-3 Selected Disease Prevention Programs in China’s Healthcare Reform (2009-2011)
- Table 4-4 Clinical Labs by Instrumentation Type in BRIC Countries
- Figure 4-4: Chinese Market for IVD Reagents ($ millions) (2004-2015)
- Figure 4-5: Regional Market Divisions for Medical Products in China (Eastern,
Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
- Table 4-5 Regional Markets for IVD Products in China (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern), 2010-2015
- Table 4-6 IVD Market Segmentation (2009) (% of sales)
- Table 4-7 IVD Market Shares by Company (2009) (%)
- Table 4-8 BRIC IVD Market Comparison (2010) ($ millions)
- Table 4-9 Selected Made-in-China Lab Supplies
- Table 4-10 Selected IVD Manufacturers in China
- Figure 4-6: IVD Product Registration and Regulatory Flowchart
CHAPTER FIVE: MEDICAL DEVICES IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015
- Figure 5-1: Cancer Mortality Rates in China - Lung, Liver, Stomach, Esophageal,
Colon, Leukemia, Brain, Breast, Pancreatic (Per 100,000) (2005)
- Figure 5-2: Chinese Population by Age (Total; 1990/2000/2009) (%)
- Figure 5-3: Composition of Chinese Hospital Sector by Number of Beds, 2000-2010
- Figure 5-4: Compositional Changes in the Hospital Sector - Private, Third-Level and Specialty Hospitals (2005-2010)
- Figure 5-5: Chinese Market for Medical Devices ($ billions) (2004-2015)
- Figure 5-6: Regional Market Divisions for Medical Products in China (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
- Table 5-1 Regional Markets for Medical Devices in China, $ billions 2010 and 2015 (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
- Figure 5-7: China Medical Device Market - Product Segment Shares
Percent, 2010 (Surgical Instrument, Disposable, Patient Monitoring,
IVD, Imaging,
Orthopedic, Other)
- Figure 5-8: Foreign-Invested Manufacturing Enterprises in China (1980-2010)
- Figure 5-9: Medical Device Registration and Approval Flowchart
CHAPTER SIX: PHARMACEUTICALS IN CHINA - MARKET OPPORTUNITIES AND CHALLENGES THROUGH 2015
- Figure 6-1: Chronic Disease Morbidity Rates in Urban China - Hypertension, Diabetes, Cerebrovascular Disease (Stroke), Chronic Obstructive Pulmonary Disease, Heart Disease (per thousand [0/00]) (2003/2008)
- Figure 6-2: Cancer Mortality Rates in China - Lung, Liver, Stomach, Esophageal, Colon, Leukemia, Brain, Breast, Pancreatic (Per 100,000) (2005)
- Table 6-1 Incidence Rates for Top Ten Notifiable Infectious Diseases (2010)
- Figure 6-3: Chinese Market for Pharmaceuticals (incl. Hong Kong) ($ billions) (2004-2015)
- Figure 6-4: Regional Market Divisions for Medical Products in China (Eastern, Northern, Central, Southern, Southwestern, Northwestern, Northeastern)
- Table 6-2 Regional Markets for Pharmaceuticals in China, $ billions, 2010-2015 (Eastern , Northern , Central , Southern , Northeastern , Southwestern , Northwestern )
- Figure 6-5: China Pharmaceutical Market - Patented Prescription, Generics, OTC Market Shares (%) (2010)
- Table 6-3: China Pharmaceutical Market (Patented Prescription and Generics only) by Product Segment, 2010 and 2015 (Cardiovascular, Gastrointestinal, Anti-Infectives, Neurotherapetuics, Oncology, Respiratory, Other)
- Figure 6-6: Foreign-Invested Manufacturing Enterprises in China (1980-2010)
- Table 6-4 Leading Medicinal Manufacturers in China (2009) (%, National Share of Aggregate Pharma/TCM/Nutritional Market)
- Table 6-5 Pharmaceutical Price Cuts (2000-2010)
- Figure 6-7: Pharmaceutical Approval and Regulatory Flowchart
More China General Pharmaceuticals Reports
Understanding Regional Chinese Health Markets by
Espicom Healthcare Intelligence
Critical information and statistics on national and regional health infrastructure and provision. An essential source of detailed key business data.
...
China Pharma Outsourcing Annual Review 2011 by
JZMed, Inc.
In our 2010 China Pharma Outsourcing Annual Review, we analyzed and forecasted the possible development trends of the Chinese pharma outsourcing market in 2011. After ...
Pharmaceuticals in China by
MarketLine
Introduction Pharmaceuticals in China industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2006-10, and forecast to 2015). The profile ...
China Chemical Pharmaceutical Industry Report, 2011 by
Research in China
In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over ...
China Pharmaceutical Raw Materials Market Report by
Beijing Zeefer Consulting Ltd.
This report presents a clear picture about the overall development of pharmaceutical raw materials market in China and the trend in recent years based on ...
See all reports like this >>
More China Reports
D&B Country RiskLine Report: China by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
Country Report China February 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Country Report China January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
D&B Country Report: China by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Wine - BRIC (Brazil, Russia, India, China) Industry Guide by
MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...
See all reports like this >>
Share this report
Other tasks Related Markets General Pharmaceuticals Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
